All In Biotech

Drugs by condition

Drugs approved for spinal muscular atrophy

Brand-name prescription drugs and biologics whose FDA label lists spinal muscular atrophy as an approved use. Matched on the label phrases: "spinal muscular atrophy".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

4

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

3

New molecular entities and new biologics

In development

6

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for spinal muscular atrophy.

  • Isembyld (Apitegromab-Mstn) · Scholar Rock INC NovelPriority reviewOrphanSep 11, 2026
  • Evrysdi (Risdiplam) · Genentech INC OrphanFeb 11, 2025
  • Evrysdi (Risdiplam) · Genentech INC NovelPriority reviewOrphanAug 7, 2020
  • Spinraza (Nusinersen Sodium) · Biogen NovelPriority reviewOrphanDec 23, 2016

All approved drugs for spinal muscular atrophy, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Survival of Motor Neuron 2 Splicing Modifier (2)

  • Evrysdi Risdiplam · Genentech INC · 2020
  • Evrysdi Risdiplam · Genentech INC · 2025

Survival Motor Neuron-2-directed RNA Interaction (1)

  • Spinraza Nusinersen Sodium · Biogen · 2016

Class not listed in FDA's data (1)

  • Isembyld Apitegromab-Mstn · Scholar Rock INC · 2026

Drugs in development for spinal muscular atrophy

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • RO7204239Phase 33 trials

    Roche (Genentech) · Obesity, Overweight, Overweight With One Weight Related Comorbidity

  • SalanersenBIIB115Phase 33 trials

    Biogen · Muscular Atrophy, Spinal, Spinal Muscular Atrophy

  • BHV-2000Taldefgrobep, BMS-986089Phase 32 trials

    Biohaven Pharmaceuticals, Inc. · Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

  • NMD670Phase 23 trials

    NMD Pharma A/S · Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease

  • ARGX-119Phase 21 trial

    argenx · Spinal Muscular Atrophy (SMA)

  • GB221Phase 21 trial

    Gemma Biotherapeutics · Spinal Muscular Atrophy Type I

More on spinal muscular atrophy: recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.